|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilson PM, Danenberg PV, Johnston PG, Lenz
HJ and Ladner RD: Standing the test of time: targeting thymidylate
biosynthesis in cancer therapy. Nat Rev Clin Oncol. 11:282–298.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van Kuilenburg AB: Dihydropyrimidine
dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur
J Cancer. 40:939–950. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Toi M, Atiqur Rahman M, Bando H and Chow
LW: Thymidine phosphorylase (platelet-derived endothelial-cell
growth factor) in cancer biology and treatment. Lancet Oncol.
6:158–166. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salonga D, Danenberg KD, Johnson M,
Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman
L, Diasio RB and Danenberg PV: Colorectal tumors responding to
5-fluoro-uracil have low gene expression levels of
dihydropyrimidine dehydrogenase, thymidylate synthase, and
thymidine phos-phorylase. Clin Cancer Res. 6:1322–1327.
2000.PubMed/NCBI
|
|
7
|
Soong R, Shah N, Salto-Tellez M, Tai BC,
Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, et al: Prognostic
significance of thymidylate synthase, dihydropyrimidine
dehydrogenase and thymidine phosphorylase protein expression in
colorectal cancer patients treated with or without
5-fluorouracil-based chemotherapy. Ann Oncol. 19:915–919. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Laufman LR, Krzeczowski KA, Roach R and
Segal M: Leucovorin plus 5-fluorouracil: an effective treatment for
metastatic colon cancer. J Clin Oncol. 5:1394–1400. 1987.PubMed/NCBI
|
|
9
|
Sakamoto E, Tsukioka S, Oie S, Kobunai T,
Tsujimoto H, Sakamoto K, Okayama Y, Sugimoto Y and Oka T, Fukushima
M and Oka T: Folylpolyglutamate synthase and gamma-glutamyl
hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer
activity. Biochem Biophys Res Commun. 365:801–807. 2008. View Article : Google Scholar
|
|
10
|
Pommier Y: Topoisomerase I inhibitors:
camptothecins and beyond. Nat Rev Cancer. 6:789–802. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shirota Y, Stoehlmacher J, Brabender J,
Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg
PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict
survival for colorectal cancer patients receiving combination
oxaliplatin and fluorouracil chemotherapy. J Clin Oncol.
19:4298–4304. 2001.PubMed/NCBI
|
|
12
|
Bohanes P, Labonte MJ and Lenz HJ: A
review of excision repair cross-complementation group 1 in
colorectal cancer. Clin Colorectal Cancer. 10:157–164. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar
|
|
14
|
Baselga J and Arteaga CL: Critical update
and emerging trends in epidermal growth factor receptor targeting
in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Elsaleh H, Joseph D, Grieu F, Zeps N, Spry
N and Iacopetta B: Association of tumour site and sex with survival
benefit from adjuvant chemotherapy in colorectal cancer. Lancet.
355:1745–1750. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iacopetta B: Are there two sides to
colorectal cancer? Int J Cancer. 101:403–408. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gervaz P, Bucher P and Morel P: Two
colons-two cancers: paradigm shift and clinical implications. J
Surg Oncol. 88:261–266. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Söreide K, Janssen EA, Söiland H, Körner H
and Baak JP: Microsatellite instability in colorectal cancer. Br J
Surg. 93:395–406. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fukushima M, Morita M, Ikeda K and
Nagayama S: Population study of expression of thymidylate synthase
and dihydropyrimidine dehydrogenase in patients with solid tumors.
Int J Mol Med. 12:839–844. 2003.PubMed/NCBI
|
|
20
|
Fukui Y, Oka T, Nagayama S, Danenberg PV,
Danenberg KD and Fukushima M: Thymidylate synthase,
dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase
mRNA and protein expression levels in solid tumors in large scale
population analysis. Int J Mol Med. 22:709–716. 2008.PubMed/NCBI
|
|
21
|
General Rules for Clinical and
Pathological Studies on Cancer of the Colon, Rectum and Anus.
Japanese Society for Cancer of the Colon and Rectum: 7th edition.
Kanehara & Co, Ltd; Kanehara, Tokyo; 2006
|
|
22
|
Lord RV, Salonga D, Danenberg KD, Peters
JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P,
DeMeester SR, et al: Telomerase reverse transcriptase expression is
increased early in the Barrett's metaplasia, dysplasia,
adenocarcinoma sequence. J Gastrointest Surg. 4:135–142. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heid CA, Stevens J, Livak KJ and Williams
PM: Real time quantitative PCR. Genome Res. 6:986–994. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gibson UE, Heid CA and Williams PM: A
novel method for real time quantitative RT-PCR. Genome Res.
6:995–1001. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kuramochi H, Hayashi K, Uchida K, Miyakura
S, Shimizu D, Vallböhmer D, Park S, Danenberg KD, Takasaki K and
Danenberg PV: Vascular endothelial growth factor messenger RNA
expression level is preserved in liver metastases compared with
corresponding primary colorectal cancer. Clin Cancer Res. 12:29–33.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ichikawa W, Uetake H, Shirota Y, Yamada H,
Takahashi T, Nihei Z, Sugihara K, Sasaki Y and Hirayama R: Both
gene expression for orotate phosphoribosyltransferase and its ratio
to dihydropyrimidine dehydrogenase influence outcome following
fluoropyrimidine-based chemotherapy for metastatic colorectal
cancer. Br J Cancer. 89:1486–1492. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoshinare K, Kubota T, Watanabe M, Wada N,
Nishibori H, Hasegawa H, Kitajima M, Takechi T and Fukushima M:
Gene expression in colorectal cancer and in vitro chemosensitivity
to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci.
94:633–638. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Inokuchi M, Uetake H, Shirota Y, Yamada H,
Tajima M and Sugihara K: Gene expression of 5-fluorouracil
metabolic enzymes in primary colorectal cancer and corresponding
liver metastasis. Cancer Chemother Pharmacol. 53:391–396. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Uchida K, Danenberg PV, Danenberg KD and
Grem JL: Thymidylate synthase, dihydropyrimidine dehydrogenase,
ERCC1, and thymidine phosphorylase gene expression in primary and
metastatic gastrointestinal adenocarcinoma tissue in patients
treated on a phase I trial of oxaliplatin and capecitabine. BMC
Cancer. 8:3862008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sameshima S, Tomozawa S, Kojima M, Koketsu
S, Motegi K, Horikoshi H, Okada T, Kon Y and Sawada T:
5-Fluorouracil-related gene expression in primary sites and hepatic
metastases of colorectal carcinomas. Anticancer Res. 28(3A):
1477–1481. 2008.PubMed/NCBI
|
|
31
|
Kumamoto K, Kuwabara K, Tajima Y, Amano K,
Hatano S, Ohsawa T, Okada N, Ishibashi K, Haga N and Ishida H:
Thymidylate synthase and thymidine phosphorylase mRNA expression in
primary lesions using laser capture microdissection is useful for
prediction of the efficacy of FOLFOX treatment in colorectal cancer
patients with liver metastasis. Oncol Lett. 3:983–989.
2012.PubMed/NCBI
|
|
32
|
Goto T, Shinmura K, Yokomizo K, Sakuraba
K, Kitamura Y, Shirahata A, Saito M, Kigawa G, Nemoto H, Sanada Y
and Hibi K: Expression levels of thymidylate synthase,
dihydropyrimidine dehydrogenase, and thymidine phosphorylase in
patients with colorectal cancer. Anticancer Res. 32:1757–1762.
2012.PubMed/NCBI
|
|
33
|
Uetake H, Ishikawa T, Matsui S and
Sugihara K: Gene expression analysis as a biomarker study for
ACTS-CC trial (TRICC0706), a phase III trial for adjuvant
chemotherapy of S-1 and UFT/LV against stage III colon cancer in
Japan. Cancer Res. 72(8 Suppl): 45162012. View Article : Google Scholar
|
|
34
|
Kawakami K, Ooyama A, Ruszkiewicz A, Jin
M, Watanabe G, Moore J, Oka T, Iacopetta B and Minamoto T: Low
expression of gamma-glutamyl hydrolase mRNA in primary colorectal
cancer with the CpG island methylator phenotype. Br J Cancer.
98:1555–1561. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sadahiro S, Suzuki T, Tanaka A, Okada K,
Nagase H and Uchida J: Association of right-sided tumors with high
thymidine phosphorylase gene expression levels and the response to
oral uracil and tegafur/leucovorin chemotherapy among patients with
colorectal cancer. Cancer Chemother Pharmacol. 70:285–291. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ricciardiello L, Ceccarelli C, Angiolini
G, Pariali M, Chieco P, Paterini P, Biasco G, Martinelli GN, Roda E
and Bazzoli F: High thymidylate synthase expression in colorectal
cancer with micro-satellite instability: Implications for
chemotherapeutic strategies. Clin Cancer Res. 11:4234–4240. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jensen SA, Vainer B, Kruhøffer M and
Sørensen JB: Microsatellite instability in colorectal cancer and
association with thymidylate synthase and dihydropyrimidine
dehydrogenase expression. BMC Cancer. 9:252009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sinicrope FA, Rego RL, Halling KC, Foster
NR, Sargent DJ, La Plant B, French AJ, Allegra CJ, Laurie JA,
Goldberg RM, et al: Thymidylate synthase expression in colon
carcinomas with microsatellite instability. Clin Cancer Res.
12:2738–2744. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Missiaglia E, Jacobs B, D'Ario G, Di Narzo
AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan
P, et al: Distal and proximal colon cancers differ in terms of
molecular, pathological, and clinical features. Ann Oncol.
25:1995–2001. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Loupakis F, Yang D, Yau L, Feng S,
Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ,
et al: Primary tumor location as a prognostic factor in metastatic
colorectal cancer. J Natl Cancer Inst. 107:dju4272015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kotake K, Honjo S, Sugihara K, Kato T,
Kodaira S, Takahashi T, Yasutomi M, Muto T and Koyama Y: Changes in
colorectal cancer during a 20-year period: an extended report from
the multi-institutional registry of large bowel cancer, Japan. Dis
Colon Rectum. 46(Suppl): S32–S43. 2003.PubMed/NCBI
|
|
42
|
Sakamoto K, Machi J, Prygrocki M, Watanabe
T, Hosoda S, Sugano M, Tomiki Y and Kamano T: Comparison of
characteristics and survival of colorectal cancer between
Japanese-Americans in Hawaii and native Japanese in Japan. Dis
Colon Rectum. 49:50–57. 2006. View Article : Google Scholar
|
